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Imiquimod is a synthetic Toll-like receptor 7 (TLR7) agonist approved for the topical treatment of actinic
keratoses, superficial basal cell carcinoma, and genital warts. Imiquimod leads to an 80–100% cure rate of lentigo
maligna; however, studies of invasive melanoma are lacking. We conducted a pilot study to characterize the
local, regional, and systemic immune responses induced by imiquimod in patients with high-risk melanoma.
After treatment of the primary melanoma biopsy site with placebo or imiquimod cream, we measured immune
responses in the treated skin, sentinel lymph nodes (SLNs), and peripheral blood. Treatment of primary
melanomas with 5% imiquimod cream was associated with an increase in both CD4þ and CD8þ T cells in
the skin, and CD4þ T cells in the SLN. Most of the CD8þ T cells in the skin were CD25 negative. We could not
detect any increases in CD8þ T cells specifically recognizing HLA-A*0201-restricted melanoma epitopes in the
peripheral blood. The findings from this small pilot study demonstrate that topical imiquimod treatment results
in enhanced local and regional T-cell numbers in both the skin and SLN. Further research into TLR7
immunomodulating pathways as a basis for effective immunotherapy against melanoma in conjunction with
surgery is warranted.
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INTRODUCTION
Invasive melanoma accounts for 4% of skin cancers, but
causesB71% of skin cancer deaths, largely due to aggressive
metastatic disease. Primary melanomas can induce immune
suppression in the sentinel draining lymph node (SLN;
Lee et al., 2005; Shu et al., 2006). Specifically, antigen
presentation by dendritic cells (DCs) can be negatively
impacted in the sentinel nodes, leading to deficient tumor-
specific T-cell induction and inefficient control of metastatic
spread (Pinzon-Charry et al., 2005). Identification of im-
munomodulating agents to enhance immune responses may
result in better systemic immunity and improved control of
metastases. After a biopsy demonstrates an invasive melano-
ma with a Breslow thickness greater than 1 mm, the current
standard of care is to immediately excise the melanoma with
wide surgical margins and to biopsy the SLN. However, the
use of immune stimulating agents before surgical removal of
the primary melanoma and SLN biopsy may provide
additional immunoprotective benefit to patients with thicker
high-risk melanoma (Erickson and Miller, 2010).
Imiquimod is a topical immunomodulator that is Food and
Drug Administration approved for use in external genital
warts, superficial basal cell carcinoma, and actinic keratosis
(Gaspari et al., 2009). It belongs to the imidazoquinoline
small-molecule family of Toll-like receptor (TLR) agonists.
TLRs are conserved receptors that are important in pathogen
recognition, as well as linking innate and acquired immunity
(Takeda and Akira, 2004). Imiquimod modulates immune
responses through activation of TLR7 (Hemmi et al., 2002)
located on endosomal membranes of antigen-presenting
cells, including myeloid and plasmacytoid DCs (pDCs),
monocytes, and macrophages. TLR7 activation induces
secretion of proinflammatory cytokines, predominantly IFN-a,
IL-12, and tumor necrosis factor-a (Stanley, 2002), and
facilitates the maturation and migratory capabilities of DCs
(Prins et al., 2006). These responses help to bridge innate and
acquired immune responses, leading to CD4þ T-helper
type-1 cell induction, as well as cytotoxic CD8þ antitumor
T-cell responses. Persistent TLR signaling may also be
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required to bypass regulatory T-cell-induced tolerance
(Yang et al., 2004). Previous studies have demonstrated that
other TLR-stimulating agents, such as CpG oligodeoxy-
nucleotide (TLR9 agonist), enhance DC responses in the
SLNs of cancer patients (Molenkamp et al., 2007).
There have been few clinical studies to systematically
evaluate neoadjuvant immunomodulators in primary
melanoma patients undergoing surgical excision. Here,
we describe a pilot study of a 2-week topical course of
imiquimod cream or placebo applied to the primary
melanoma site before surgical excision of tumor and SLN
biopsy. Cellular immunological parameters in the skin
and lymph nodes were evaluated following treatment. We
hypothesized that treatment of primary cutaneous melanoma
with imiquimod before surgery would lead to a program of
inflammation at the tumor site and SLN that might enhance
systemic antimelanoma immunity. Because enhanced DC
responses might lead to increased tumor antigen presentation
and naı¨ve T-cell induction, we included in the study
measurements of melanoma antigen-specific T-cell responses
in the peripheral blood before and after therapy.
RESULTS
Patient selection and treatment
A total of 14 patients with primary melanoma tumors
measuring 41.0 mm Breslow thickness were enrolled in
the study. Patients were randomly assigned to preoperative
topical administration of either 5% imiquimod cream or
vehicle (placebo) cream to their tumor areas, every day for
2 weeks before surgical removal of tumor and SLNs. The final
day of treatment was the day before surgery (day 1). Blood
samples were obtained from each patient before and after
treatment (days 14 and 0). Tumor sites were examined and
photographed on these days for comparison. One patient
from each group did not complete the SLN resection for
clinical reasons unrelated to this study, and these patients
were not included in the SLN analysis.
No severe local or systemic adverse reactions were
observed in any of the patients after 2 weeks of treatment.
Signs of local inflammation, including erythema and
edema, were expected to occur in some patients in the
imiquimod-treated group. Four out of the six analyzable
imiquimod-treated patients had clinical evidence of a
pharmacological response, i.e., obvious signs of local
inflammation, including erythema, crusting, or scaling in
the area of treatment. Two imiquimod-treated patients had no
clinical evidence of a pharmacological response, and
displayed no visible differences in the skin before and after
treatment. The patient with the most overt, marked inflam-
matory response (patient 2) had an obviously enlarged SLN
(greater than 1 cm). However, despite having obvious visible
tumor before treatment on day 14 (Figure 1), melanoma
cells could not be detected in the excised tumor area or SLN
on day 0. In the placebo-treated group, only one patient
developed mild erythema, whereas five others displayed
no clinical differences between pre- and posttreatment.
On day 0, tumors and SLNs were surgically removed from
all patients.
Local cutaneous effects of TLR7 activation
On the basis of prior reports, we hypothesized that topically
applied imiquimod would lead to localized skin inflamma-
tion. After applying cream topically for 2 weeks, we
evaluated patients’ primary tumor sites for the infiltration of
immune cells following imiquimod or placebo treatment.
Paraffin-embedded serial sections were stained with anti-
bodies to identify lymphocytes and monocyte/macrophage/
dendritic lineage cells, and assessed by immunohistochem-
istry (IHC). Significantly higher levels of CD3þ T cells, both
CD4þ and CD8þ , were observed in the local skin regions
of the primary tumor site following treatment with imiqui-
mod, compared with placebo (Figure 2a). Subtype analysis
of these cells revealed that most CD8þ cells were
CD25 (separately submitted manuscript). During analysis
of non-lymphocyte markers, conversely, we were unable to
detect significant differences between imiquimod- and
placebo-treated groups in levels of myeloid DCs (CD1aþ
and CD11cþ ), macrophages (CD14þ and CD68þ ), anti-
gen-presenting cells (HLA-DRþ , S100þ ), pDCs (CD123þ ),
or Langerhans cells (Langerinþ ; Figure 2b). Within the
imiquimod-treated group, patients displaying the highest
levels of most immune markers in the skin by IHC
corresponded with the clinically visible responders. How-
ever, the study was not powered to permit further statistical
analysis based on this clinical response classification within
the imiquimod group.
Immunological effects of TLR7 activation in SLN
Fresh SLN sections were obtained before histopathological
analysis, and single-cell suspensions were prepared for flow
cytometric quantitation of immune cell numbers. Antibody
staining of lymph node cells was performed using a similar
array of biomarkers as in the skin, but also included CD209
and CD83 for a subset of patients. As in the skin, imiquimod
treatment induced increased percentages of CD3þ lympho-
cytes compared with placebo. The percentage of CD4þ cells
was significantly higher and the percentage of CD8þ cells
trended higher in the imiquimod group as well (Figure 3a).
We used both IHC and flow cytometry to quantitate
the levels of monocyte/macrophage/DC infiltration of the
lymph nodes. Single stains with the antibodies used in
Figure 2 revealed no significant differences between placebo-
treated and imiquimod-treated groups, as shown by IHC
(Figure 3b). A subset of patients was assessed for additional
monocyte lineage surface markers by flow cytometry. We
were unable to detect significant differences in CD123þ ,
Day – 14 Day – 7 Day 0
Figure 1. Melanoma site of ‘‘responder’’, before and after treatment with
imiquimod. Patient applied topical imiquimod to tumor site starting on
day 14, and ending on day 1, before surgery on day 0.
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CD123þCD11c (defining a pDC subset), and CD209þ
populations between placebo- and imiquimod-treated groups
(Figure 3c). Double staining with CD83 allowed assessment
of the activation status of these populations. These measure-
ments also failed to detect differences in the numbers of
activated CD1aþ , CD11cþ , and CD209þ populations
between the two groups of patients (Figure 3d).
Assessment of melanoma-specific peripheral T cells before and
after imiquimod treatment
Lymphocytes were purified from peripheral blood mono-
nuclear cells (PBMCs) harvested from patients before and
after imiquimod (or placebo) treatment, and potential tumor
specificity was assessed in the subset of HLA-A*0201-positive
patients using tetramer staining assays. We chose defined
HLA-A*0201-binding epitopes derived from MART-1, tyro-
sinase, and gp100, as these represent commonly found T-cell
receptor specificities in melanoma patients (Comin-Anduix
et al., 2008). Following staining and flow cytometric analysis,
CD8þ cells that stained positive with these tetramers were
assessed. Slight increases in the percentage of tetramerþ
cells were seen in some individuals following the 2-week
treatment period (Figure 4). However, in terms of overall
number of responses observed, there were no significant
differences between placebo- and imiquimod-treated groups
for any of the three tumor antigen specificities analyzed.
DISCUSSION
Imiquimod has shown clinical efficacy in a number of
different skin neoplasms, including superficial basal cell
carcinoma and actinic keratoses, but its exact mechanism of
action is largely undefined. Imiquimod has been widely used
off-label in cases of lentigo maligna and cutaneous metastatic
melanoma (Naylor et al., 2003; Buettiker et al., 2008; Cotter
et al., 2008; Powell et al., 2009). In addition, others and we
have demonstrated the ability of imiquimod to enhance
vaccine-associated protection against melanoma in mice
(Craft et al., 2005; Prins et al., 2006; Ma et al., 2010).
Although surgical excision is generally the main treatment
modality for both lentigo maligna and invasive melanoma,
imiquimod has been used in patients with confounding
comorbidities that limit their surgical candidacy and in
patients with tumors in anatomic areas that would lead to
esthetic or functional impairments. Currently, only case
studies have been reported on imiquimod as a monotherapy
for cutaneous metastases of melanoma, although there has
been a phase I/II study of topical imiquimod combined with
intralesional IL-2 that demonstrated some clinical responses
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Figure 2. Immune biomarkers in local tumor sites. Skin sections from placebo-treated (closed circles) and imiquimod-treated (open squares) patients were
assessed by immunohistochemistry. Percent of areas staining positive for lymphocyte markers (a) and monocyte/macrophage/dendritic cell lineage markers (b)
were quantitated using Image-Pro software. Means±SEM are shown, N¼ 7 for all groups except CD8–imiquimod (6), HLA-DR–placebo (6), and
HLA-DR–imiquimod (3). P-values for CD3¼ 0.01, CD4¼ 0.03, and CD8¼0.01. *Po0.05.
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in cutaneous metastases (Green et al., 2008). Topical
imiquimod treatment can lead to 75% cure rates of
melanoma in situ without surgery (Cotter et al., 2008).
However, overall data remain inconclusive, because of small
study sizes and short follow-up periods (Rajpar and Marsden,
2006; Erickson and Miller, 2010). We hypothesized that
topical imiquimod treatment of high-risk invasive primary
melanoma in humans would lead to increased antitumor
immune responses in the skin and SLN. In this pilot study, we
identified, quantified, and compared local tumor site and
draining lymph node immune responses in imiquimod-
and placebo-treated primary malignant melanoma patients.
Clinical outcomes associated with treatment were not the
focus of this study.
Our data demonstrate that topical imiquimod treatment
significantly elevates levels of CD4þ and CD8þ lympho-
cytes, both locally in the skin and in the draining SLNs, as
compared with patients treated with placebo. We were
unable to detect, however, significant differences in the levels
of DCs, macrophages, Langerhans cells, or other antigen-
presenting cells. The fact that this was a pilot study with small
numbers of patients allowed only large differences between
groups to be detected. Previous studies have shown evidence
that topical imiquimod treatment is associated with local
infiltration of both myeloid and lymphoid immune cells
(Torres et al., 2007; DeGiorgi et al., 2009). Infiltration of
T lymphocytes and DCs into superficial basal cell carcinomas
(Barnetson et al., 2004) and actinic keratoses (Ooi et al.,
2006) were associated with imiquimod treatment. We
initially hypothesized that imiquimod-treated patients would
have either increased numbers of monocyte lineage cells
or higher activation levels. Although we examined the
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Figure 3. Immune biomarkers in primary sentinel lymph nodes by flow cytometry or immunohistochemistry (IHC). Lymph node sections and single-cell
suspensions from placebo-treated (closed circles) and imiquimod-treated (open squares) patients were assessed by IHC and flow cytometry, respectively.
Lymphocytes were quantified by flow cytometry (a), monocyte/macrophage/dendritic cell (DC) lineage cells were quantified by IHC (b) or flow cytometry (c),
and activation markers on monocyte/DC cells were quantified by flow cytometry (d). Means±SEM are shown, N¼ 6 for all groups except in the following:
(b) CD14–placebo (5), HLA-DR–-placebo (5), and HLA-DR–imiquimod (2); (c) all subgroups were 4 or 3; (d) CD209/CD83 was 4 and 3. P-values in a for
CD3¼ 0.02, CD4¼0.04, and CD8¼ 0.12. pDC, plasmacytoid DC. *Po0.05.
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Figure 4. Tetramer staining of peripheral blood mononuclear cell (PBMC)
CD8þ lymphocytes following imiquimod or placebo treatment.
Lymphocyte-enriched PBMC fractions from HLA-A*0201-positive patients
(four placebo-treated and five imiquimod-treated) were assessed for
recognition of HLA-A*0201-binding melanoma epitopes derived from
MART-1, tyrosinase (Tyr), or gp100, by tetramer staining. Differences between
pre- and posttreatment were assessed per individual, and placebo- and
imiquimod-treated group differences compared using the Wilcoxon
signed-rank test.
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activation marker CD83 and could not detect increased
levels in the small number of imiquimod-treated patients in
this study, we did not examine potential functional
differences, such as cytokine or chemokine expression,
which might influence lymphocyte infiltration.
The predominant cell type that responds to TLR7 stimula-
tion in humans is the pDC (Gibson et al., 2002), identified in
this study by CD123þCD11c staining, although conven-
tional myeloid DCs, identified as CD11cþ , have also been
shown to respond to TLR7 agonists (Ito et al., 2002). One
major response of activated pDCs is the expression of type I
IFNs (IFNa and IFNb) via signaling through NFkB. Indeed, a
microarray analysis of imiquimod treatment of superficial
basal cell carcinomas and cutaneous T-cell lymphomas
revealed increased expression of IFNa-induced genes that
correlated with higher numbers of tumor-infiltrating activated
pDCs (Urosevic et al., 2005). Our data did not reveal
significant differences in pDC populations in the SLN or the
excised tumor; however, the previous study was performed
only 5 days following initiation of imiquimod treatment,
compared with 2 weeks in our study. In addition to pDCs,
other cell types expressing TLR7 may also be involved in the
inflammation observed in our study, and in the clinical effect
observed in the treatment of skin tumors here and in prior
reports. These cells include myeloid DCs, T cells, B cells,
and monocyte/macrophages. Although statistical significance
was not reached because of the limited sample size, cells
expressing the monocyte/macrophage marker CD68 were
detected in higher numbers in imiquimod-treated tumor sites
than in skin treated with placebo cream. Cytokine release
may also lead to indirect effects on other cell subpopulations,
reflecting the complex interrelationships among immune
cells during imiquimod treatment.
Signs of localized visible inflammation are strong
predictors of therapeutic benefit in lentigo maligna patients
treated with imiquimod (Powell et al., 2009). Among the
imiquimod-treated patients in this study, varying degrees of
clinical inflammation were evident following the 2-week
treatment course. Comparing posttreatment with pretreat-
ment, four out of six patients treated with imiquimod showed
clinical inflammation—erythema, crusting, or scaling—
whereas two of six had no obvious visible changes after
14 days of treatment. Thus, because 5% topical imiquimod
was not always associated with obvious local changes, we
characterized subsets within the treatment group as pharma-
cological responders and nonresponders based on visible
local inflammation of the skin. It is possible that genetically
distinct subsets of the population respond differently
to immunomodulation by imiquimod. Single-nucleotide
polymorphisms have been described for TLR7 and TLR8,
including alleles that are associated with disease outcomes
for HCV (Schott et al., 2008) and HIV infection (Oh et al.,
2008), suggesting that genetic variation might potentially
contribute to varied clinical responses to TLR ligand
stimulation. Whatever the cause of variability in TLR ligand
responses, larger future studies could be designed to account
for individual patients having varying degrees of pharma-
cological responses to imiquimod.
Recent evidence has implicated CD8þ /CD25/gran-
zyme Bþ /perforinþ T cells as a population that is capable
of responding immediately to immune stimulation (separately
submitted manuscript). Activation and proliferation of T cells
through the TCR normally leads to CD25 upregulation. The
increased numbers of CD8þ T cells that we observed in
treated skin and SLN sections of imiquimod-treated patients
were found by co-staining to be CD25 negative (data in a
separate manuscript under review). This observation suggests
that these cells are likely infiltrating and proliferating in
response to TLR7 stimulation in the absence of antigen.
In patient PBMCs, we were unable to detect any T cells
that recognize epitopes from three common melanoma
targets, MART-1, tyrosinase, and gp-100. Because imiquimod
was applied to tumor sites before surgical excision, the tumor
itself might serve as an antigen source for endogenous DCs
that are activated by imiquimod. Any antigen-loaded DC
could then traffic to the draining lymph nodes to activate
tumor-specific T cells. The fact that no melanoma antigen-
specific T cells could be detected in PBMCs from these
melanoma patients does not rule out their existence, as
the epitopes examined do not represent a complete array of
potential targets that might be recognized by T cells. In
addition, any potentially generated antigen-specific T cells
might be predicted to leave the circulation and home to the
tumor, thus precluding their detection in the blood.
Ultimately, larger studies with longer follow-up times
are needed to determine the importance of CD8þ /CD25
T cells, or whether imiquimod-induced infiltration of T cells
into the skin and SLN leads to increased circulating
melanoma antigen-specific T cells or clinical survival benefit.
Many clinicians and scientists hypothesize that immune-
based therapies delivered before the SLNs are excised from
patients with melanoma could result in improved systemic
immunosurveillance for micrometastases. Because the risk of
topical imiquimod use is exceedingly low, the results from
this pilot study suggest that a large-scale randomized,
placebo-controlled clinical trial may be warranted. The
proposed trial would use imiquimod or other TLR agonists
as topically applied, presurgical neoadjuvants to determine
whether long-term, disease-free survival or overall survival is
improved. Further characterization of the effector cells
induced by imiquimod and the mechanisms involved
in tumor clearance are also warranted.
MATERIALS AND METHODS
Study design, patients, and treatment schedule
This prospective pilot study was designed to determine the clinical
variability of responses to topical imiquimod in patients with high-
risk primary melanoma, and was modeled after a previous SLN
analysis performed in melanoma patients (Vuylsteke et al., 2004).
Thus, although the study was not powered to detect differences in
clinical outcomes, it was still designed as a randomized, double-
blind, placebo-controlled study to model potential future applica-
tions. For this pilot study, the target enrollment was n¼ 6 in each
group. Inclusion criteria were the following: 18 years of age and
older, and diagnosis of primary melanoma with a pathological
Breslow thickness greater than 1.0 mm. Exclusion criteria included
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the following: primary biopsy of the wide excisional type with
depth-appropriate margins, location of the tumor on the head and
neck, prior treatment with immunotherapy or chemotherapy,
ongoing immunotherapy, prior diagnosis with autoimmune disorder,
presence of comorbid conditions precluding lymph node biopsy,
evidence of any clinically evident metastases, and pregnancy and/or
breastfeeding. All patients received the standard of care for high-risk
melanoma including presurgical staging work-up, wide local
excision of tumor, lymphoscintigraphy and SLN biopsy, and
postsurgical care. Fourteen patients enrolled in the study after giving
written, informed consent. Patients were randomized in a 1:1 ratio to
receive imiquimod 5% cream (3M Pharmaceuticals, Saint Paul, MN,
and later Graceway Pharmaceuticals, Bristol, TN) or vehicle cream
(3M Pharmaceuticals and later Graceway Pharmaceuticals). On day
14 before surgical excision, primary lesions were photographed
and 100 ml of blood was collected for pre-therapy immune
monitoring studies and HLA typing. Starting on day 14, patients
were instructed to apply the cream (250 mg) once daily over the
affected area for 14 days. Patients were not advised to occlude the
area. Patients were evaluated on day 7 and a second photograph of
the tumor site was taken. On the day of surgery (day 0), a
posttreatment photograph was taken and another 100 ml of blood
was obtained for posttherapy immunoassays. Patients then under-
went wide excision of the tumor and SLN biopsy using standard
surgical techniques, and samples were processed for IHC, flow
cytometry, and/or immunoassays as described below. This study was
approved by the Institutional Review Board at the Los Angeles
Biomedical Research Institute and the University of California Los
Angeles (UCLA), and was conducted under Good Clinical Practices
guidelines at the Harbor-UCLA Medical Center and the UCLA
Medical Center, as well as adherence to the declaration of Helsinki
Guidelines.
IHC of paraffin-embedded tumor
Sections of excised tumors were placed in 10% formalin and
processed as typically performed by the Pathology department.
Serial sections from the paraffin-embedded blocks were subse-
quently obtained and evaluated for infiltration of immune cells using
standard IHC procedures. Antibodies against CD3 (BD Biosciences,
Mountain View, CA), CD4 (US Biological, Swampscott, MA), CD8
(Ancell, Bayport, MN), CD14 (Novocastra, Buffalo Grove, IL), CD1a
(US Biological), S100 (US Biological), Langerin (US Biological),
CD68 (US Biological), CD83 (US Biological), CD86 (Abcam,
Cambridge, UK), CD11c (Abcam), CD123 (US Biological), and
HLA-DR (US Biological) were used for staining. Image analysis of
stained slides was performed by an observer blinded to the treatment
assignment using the Image-Pro Plus software (Media Cybernetics,
Silver Spring, MD). A compiled image of the region containing the
tumor was taken for each slide ( 10), and stained areas within the
tumor were measured using the color segmentation function. For
each interpretable slide, the observer measured percentages of
positively stained area as a function of the total area of the epidermis
or dermis containing the tumor.
Isolation of SLN cells
SLNs were collected immediately after dissection and placed in
sterile, ice-cold medium. Nodes were bisected and viable cells were
collected by removing a thin, cross-sectional slice of the interior
of the node in a sterile manner. Tissue was incubated in complete
medium (IMDM (Invitrogen, Carlsbad, CA), 10% human AB
Serum (Cellgro, Manassas, VA), 50 IU ml1 penicillin–streptomycin
(Invitrogen), and 0.05 mmol/2-mercaptoethanol (Invitrogen))
containing 0.01% DNase I (Sigma, St Louis, MO) and 0.14%
collagenase A (Roche, Pleasanton, CA) for 45 minutes, and subse-
quently macerated between frosted glass slides to obtain a single-cell
suspension. Cells were then washed with complete medium,
counted, and processed for flow cytometry or IHC.
Flow cytometry of SLN cells
Isolated SLN cells were resuspended in IMDM supplemented with
10% human AB serum to block FcgIII/IIR (CD16/CD32). Cells were
stained for the following markers obtained from BD Pharmingen
(San Diego, CA): CD1a-FITC, CD3-FITC, CD4-PE, CD8-PE, CD11c-
PECy5, CD14-FITC, CD83-PE, CD86-PECy5, CD123-PE, and
CD209-FITC. Matched isotype monoclonal antibodies served as
negative controls. Subsequently, cells were analyzed by flow
cytometry (FACSCalibur, BD Biosciences, Mountain View, CA) at
100,000 events per measurement, and positive gates for each
biomarker were defined.
IHC of SLN
Immunohistochemical analysis of immune cells in the SLN was
performed as described above. IHC results are reported for each SLN
as the percentage of the total nodal area positively stained for the
specified marker. All slides were evaluated without knowledge of
the SLN tumor status or treatment group.
Blood collection and cryopreservation
Patients underwent two peripheral blood collections of 100 ml
whole blood: once before treatment initiation on study day 14, and
once following treatment, on day 0. Blood samples from day 14
were sent to UCLA Genetics Laboratory for HLA-A*0201 typing.
PBMCs were obtained by Ficoll–Hypaque (GE Healthcare,
Piscataway, NJ) centrifugation of whole blood. PBMCs were
cryopreserved at a concentration of 1 107 per ml in RPMI
(Invitrogen) supplemented with 20% (v/v) heat-inactivated human
AB serum (Cellgro) and 10% DMSO (Sigma) at 80 1C, to allow for
large batch processing on a single day.
Peptides and tetramer analysis
Tetramer analysis was performed on HLA-A*0201-positive patients,
using the following HLA-A*0201-binding peptide epitopes:
MART-126–35 (ELAGIGILTV), tyrosinase368–376 (YMDGTMSQV),
and gp100209–217 (ITDQVPFSV), representing three immunodomi-
nant tumor antigens, as well as negative control ((AFP)325–332
(GLSPNLNRFL)) and positive control ((CMV)pp65495–503
(NLVPMVATV)) epitopes. All tetramers were purchased from
Beckman Coulter, San Diego, CA, as peptide preloaded reagents,
and the assay was performed as described previously (Comin-Anduix
et al., 2006). Briefly, each patient’s PBMCs were thawed simulta-
neously and treated with DNase for 1 hour at 37 1C. Further, 1 106
cells were stained at room temperature for 30 minutes with each MHC
tetramer, plus CD8-FITC (Caltag, Carlsbad, CA), and a CD4/CD13/
CD19 antibody cocktail (Caltag) for gating. Cells were subsequently
washed and analyzed immediately using a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA). Lymphocytes were gated
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based on forward and side scatter, and those positive for CD4/CD13/
CD19 were gated out. The percentages of CD8þ cells that stained
with tetramer before and after treatment were measured and
compared using a standardized gating algorithm. Results were
analyzed based on the criteria defined previously (Comin-Anduix
et al., 2006).
Statistical analysis
The stained area percentages and the flow cytometric data in the
primary tumor and SLN studies were presumed to have normal
distributions based on previous measurements. The mean and
difference in the percentage of area (IHC) or cell number (flow
cytometry) stained in the melanoma and lymph node tissue samples
for imiquimod-treated versus placebo groups were compared using
an unpaired two-tailed t-test. Pre- and posttreatment values of
tetramer staining were analyzed using the Wilcoxon signed-rank
test. P-values of o0.05 were considered to be significant, and
multiple comparison adjustments were not applied, given the
number and nature of the cell markers being analyzed. Changes
in cell counts were summarized in six imiquimod-treated and six
placebo patients with means and standard deviations, and with the
group difference 95% confidence interval for the estimated
treatment effect.
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